Hypoglycemic, lipid-lowering and metabolic regulation activities of metforminium decavanadate (H2Metf)3 [V10O28]·8H2O using hypercaloric-induced carbohydrate and lipid deregulation in Wistar rats as biological model.
Because of the increasing global spread of type 2 diabetes mellitus, there is a need to develop new antidiabetic agents. Recently we have synthesized new decavanadates using metformin as counterion. In particular, the compound containing three metforminium dications has been obtained in high yield and has been completely characterized. Biological studies using Wistar rats that have been fed with a high caloric diet inducing insulin resistance and metabolic syndrome were carried out. Results of the impact on key biochemical parameters mediated by metformin alone and the new compound are here presented. The metforminium decavanadate (H2Metf)3[V10O28]·8H2O, abbreviated as Metf-V10O28, was shown to have pharmacological potential as a hypoglycemic, lipid-lowering and metabolic regulator, since the resulting compound made of the two components with antidiabetic activities, reduces both dosage and time of administration (twice a week). Hence, due to the beneficial effects induced by the metforminium decavanadate we recommend to continue the exploration into the mechanism and toxicology of this new compound.
['Treviño|Samuel|S|', 'Sánchez-Lara|Eduardo|E|', 'Sarmiento-Ortega|Víctor Enrique|VE|', 'Sánchez-Lombardo|Irma|I|', 'Flores-Hernández|José Ángel|JÁ|', 'Pérez-Benítez|Aarón|A|', 'Brambila-Colombres|Eduardo|E|', 'González-Vergara|Enrique|E|']
D000818:Animals D050260:Carbohydrate Metabolism D059305:Diet, High-Fat D044882:Glucose Metabolism Disorders D006949:Hyperlipidemias D007004:Hypoglycemic Agents D000960:Hypolipidemic Agents D050356:Lipid Metabolism D008297:Male D008687:Metformin D051381:Rats D017208:Rats, Wistar D014018:Tissue Distribution D014638:Vanadates
Decavanadate Diabetes Metformin Metabolic syndrome Bioinorganic vanadium chemistry